Nektar Therapeutics (NKTR) Stock Analysis — Probabli.AI
AI-powered analysis for NKTR (Nektar Therapeutics): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
Last price: $56.62 · Market cap: $1.9B · AI outlook: Bullish
Nektar Therapeutics represents a high-risk, high-reward investment opportunity primarily driven by its promising pipeline assets and strong analyst favor. Its positive FDA Fast Track designation, expanded R&D partnerships, and recent trial results contribute to bullish sentiment. Financial and competitive risks should not be ignored, but these are outweighed by mid-to-long term growth potential.
Probabilistic 1-Year Outlook
- Bull 35% · Neutral 50% · Bear 15%
- 1-year price estimates — P10: $50 / P50: $95 / P90: $140
- Recent positive developments in R&D partnerships and a promising FDA Fast Track designation set a strong bullish case. Although the financials such as earnings show losses, analysts are highly optimistic with a strong…
5-Year Outlook
- Bull 40% · Neutral 40% · Bear 20%
- 5-year price estimates — P10: $36 / P50: $176 / P90: $350
SWOT Highlights
- Strength: Promising pipeline with FDA Fast Track designation
- Strength: Strong analyst support and consensus targeting high returns
- Risk: Negative earnings with sizable losses
- Risk: No current revenue growth projected
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
10 Wall Street analysts rate NKTR a STRONG BUY with a mean price target of $149.63.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
NKTR forecast details · NKTR sentiment details · NKTR insider activity
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.